Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zhejiang Hisun Enters Cancer Collaboration with Ambrx

publication date: Apr 30, 2014
Zhejiang Hisun Pharma will collaborate with Ambrx, a San Diego clinical-stage biotech, to develop bispecific cancer treatments based on Ambrx’s technology. Hisun will own China rights to the products, while Ambrx will retain ex-China rights and receive royalties on any China sales. Hisun will manufacture the product to cGMP standards for clinical and commercial supplies on a global basis. Ambrx’s technology, which it calls Protein Medicinal Chemistry™, optimizes proteins and antibodies to create long-acting proteins, bi-specifics and antibody drug conjugates. More details....

Stock Symbol: (SHA: 600267)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital